Literature DB >> 12598432

Utilities associated with diabetic retinopathy: results from a Canadian sample.

S Sharma1, A Oliver-Fernandez, J Bakal, H Hollands, G C Brown, M M Brown.   

Abstract

BACKGROUND/AIMS: To report patient based utilities, using the time trade-off technique, associated with visual loss secondary to diabetic retinopathy in a sample of Canadian patients. In addition, to compare these utility values with a sample collected in a similar manner in a tertiary care practice in the United States.
METHODS: A cross sectional study of eligible patients with diabetic retinopathy presenting to a tertiary facility was performed. Demographic and clinical variables (including Snellen visual acuity), and utilities were collected both through chart review and standardised interviews with diabetic patients.
RESULTS: 221 patients with diabetic retinopathy were eligible for this study and completed the interview. The mean age was 63.5 (SD 12.5) years, and 48.4% were female. Over 35% of the sample had visual acuity in the affected eye of 6/60 or worse. The mean utility for the sample was 0.79 (SD 0.23). The mean utility from this sample did not differ significantly from that obtained from a series of patients with diabetic retinopathy who were referred to a tertiary facility in the United States (mean 0.77, SD 0.21, p=0.313). Our cross border comparison had a power of 95% to detect a difference in utility of 0.1 between the two groups.
CONCLUSION: On average, Canadian patients with diabetic retinopathy were willing to trade off over 20% of their remaining lifespan in order to eliminate their ocular disease. The mean utility obtained from our sample of Canadian patients with diabetic retinopathy was not statistically different from that obtained from a similar sample of American patients.

Entities:  

Mesh:

Year:  2003        PMID: 12598432      PMCID: PMC1771570          DOI: 10.1136/bjo.87.3.259

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  Utility values and age-related macular degeneration.

Authors:  G C Brown; S Sharma; M M Brown; J Kistler
Journal:  Arch Ophthalmol       Date:  2000-01

2.  The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors:  S Sharma; G C Brown; M M Brown; H Hollands; G K Shah
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

3.  Improvement in quality of life from photodynamic therapy: a Canadian perspective.

Authors:  S Sharma; H Hollands; G C Brown; M M Brown; G K Shah; S M Sharma
Journal:  Can J Ophthalmol       Date:  2001-10       Impact factor: 1.882

4.  Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis.

Authors:  G C Brown; M M Brown; S Sharma; B Busbee; H Brown
Journal:  Retina       Date:  2000       Impact factor: 4.256

5.  Converting visual acuity to utilities.

Authors:  S Sharma; G C Brown; M M Brown; G K Shah; K Snow; H Brown; H Hollands
Journal:  Can J Ophthalmol       Date:  2000-08       Impact factor: 1.882

6.  Reliability of the time trade-off technique of utility assessment in patients with retinal disease.

Authors:  H Hollands; M Lam; J Pater; D Albiani; G C Brown; M Brown; A F Cruess; S Sharma
Journal:  Can J Ophthalmol       Date:  2001-06       Impact factor: 1.882

7.  Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization.

Authors:  G C Brown; M M Brown; S Sharma; H Brown; W Tasman
Journal:  Ophthalmology       Date:  2000-07       Impact factor: 12.079

8.  A cost-utility analysis of interventions for severe proliferative vitreoretinopathy.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Brandon Busbee; Jennifer Landy
Journal:  Am J Ophthalmol       Date:  2002-03       Impact factor: 5.258

9.  Incremental cost-effectiveness of initial cataract surgery.

Authors:  Brandon G Busbee; Melissa M Brown; Gary C Brown; Sanjay Sharma
Journal:  Ophthalmology       Date:  2002-03       Impact factor: 12.079

10.  Utility values and diabetic retinopathy.

Authors:  M M Brown; G C Brown; S Sharma; G Shah
Journal:  Am J Ophthalmol       Date:  1999-09       Impact factor: 5.258

View more
  15 in total

1.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 2.  A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.

Authors:  Tom W C Lung; Alison J Hayes; Andrew Hayen; Andrew Farmer; Philip M Clarke
Journal:  Qual Life Res       Date:  2011-04-07       Impact factor: 4.147

3.  Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada.

Authors:  Daria J O'Reilly; Feng Xie; Eleanor Pullenayegum; Hertzel C Gerstein; Janet Greb; Gord K Blackhouse; Jean-Eric Tarride; Jim Bowen; Ron A Goeree
Journal:  Qual Life Res       Date:  2011-01-08       Impact factor: 4.147

4.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

5.  Variation in treatment preferences and care goals among older patients with diabetes and their physicians.

Authors:  Marshall H Chin; Melinda L Drum; Lei Jin; Morgan E Shook; Elbert S Huang; David O Meltzer
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

6.  Lower visual acuity predicts worse utility values among patients with type 2 diabetes.

Authors:  David H Smith; Eric S Johnson; Allen Russell; Brian Hazlehurst; Cecilia Muraki; Gregory A Nichols; Allen Oglesby; Jonathan Betz-Brown
Journal:  Qual Life Res       Date:  2008-10-30       Impact factor: 4.147

7.  Patient perceptions of quality of life with diabetes-related complications and treatments.

Authors:  Elbert S Huang; Sydney E S Brown; Bernard G Ewigman; Edward C Foley; David O Meltzer
Journal:  Diabetes Care       Date:  2007-07-10       Impact factor: 19.112

8.  Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.

Authors:  C Hopley; G Salkeld; J J Wang; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

9.  The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy.

Authors:  Louis S Matza; Matthew D Rousculp; Karen Malley; Kristina S Boye; Alan Oglesby
Journal:  Health Qual Life Outcomes       Date:  2008-11-07       Impact factor: 3.186

Review 10.  Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review.

Authors:  Edith Poku; John Brazier; Jill Carlton; Alberto Ferreira
Journal:  BMC Ophthalmol       Date:  2013-12-04       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.